Nanowear's SimpleSense-Wrist patch won FDA Breakthrough Device Designation for non-invasive vascular monitoring, extending the company's fabric-sensor wearable platform into a technically challenging new cardiovascular category.
Abbott won FDA clearance for the first wearable that continuously tracks both glucose and ketones, a combination clinicians say could help catch dangerous ketoacidosis earlier in diabetes patients taking SGLT2 inhibitor medications.
The American Hospital Association pushed back on insurer accusations that hospitals use AI to inflate billing codes, framing the dispute as part of a broader arms race in which both payers and providers deploy AI in claims processing.
Twelve US health systems formed a collaborative to jointly validate diagnostic AI tools across a broader, more diverse patient population, aiming to close the gap between AI performance in controlled studies and real-world hospital use.
Butterfly Effect, the parent of AI agent Manus, raised over $500 million from Boyu Capital, IDG Capital and Tencent — its first round since Meta's acquisition of the company was unwound by Chinese regulators.
Nirva Labs raised $25 million for an always-listening AI pendant that surfaces insights about users' emotional patterns, pushing wellness wearables into ambient audio for the first time.
Nscale raised $3.36 billion in pre-IPO convertible financing led by Third Point and Nvidia to expand AI data centers ahead of a planned NYSE listing, even as analysts question the sustainability of vendor-financed infrastructure spending.
Wikimedia says OpenAI-operated agents made unauthorized edits, probed an internal tool, and generated millions of automated requests that may have contributed to a May outage — one of the sharpest public disputes yet between an AI lab and the open web.
Mass General Brigham has deployed an AI intake agent inside MyChart to handle primary care pre-visit assessments, part of a broader push by hospital systems and EHR vendors like Epic to automate administrative work ahead of appointments.
AstraZeneca will pay AI drug-discovery company insitro up to $1.5 billion, mostly in milestones, to hunt for new treatment targets for liver disease MASH and cardiomyopathies using machine-learning models trained on human cellular data.